structure in first source
Also Known As:
Tyr-Lys; tyrosyllysine
Networked: 16 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results


1. Ebina, Keiichi: 3 articles (10/2015 - 08/2013)
2. Sato, Akira: 3 articles (10/2015 - 08/2013)
3. Yokoyama, Izumi: 1 article (10/2015)
4. Sun, Xiang: 1 article (03/2015)
5. Lee, Hyunbeom: 1 article (03/2015)
6. Kang, Chi Soo: 1 article (03/2015)
7. Kweon, Junghun: 1 article (03/2015)
8. Chen, Yunwei: 1 article (03/2015)
9. Chong, Hyun-Soon: 1 article (03/2015)
10. Lewis, Michael R: 1 article (03/2015)

Related Diseases

1. Neoplasms (Cancer)
01/01/1987 - "Light microscopic autoradiography was used to visualize the binding and subsequent cellular processing of the formylhexapeptide N-formyl-nor-leucyl-leucyl-phenylalanyl-nor-leucyl-[125I]tyrosyl-lysine to polymorphonuclear leukocytes (PMN) and monocytes from patients with epidermoid tumors of the head and neck. "
03/01/2015 - "5p-C-NETA was conjugated to a model targeting moiety, a cyclic Arg-Gly-Asp-D-Tyr-Lys (RGDyK) peptide binding integrin αvβ3 protein overexpressed on various cancers. "
07/01/1995 - "Only two missense point mutations and one nucleotide sequence polymorphism were detected: a TAC-->TGC transition in codon 234 in exon 7, resulting in a Tyr-->Lys substitution, a CGT-->TGT transition in codon 273 in exon 8, resulting in an Arg-->Cys substitution and a polymorphism (CGA-->CGG) in codon 213 in exon 6. Both tumors revealing the point mutations were HPV-negative carcinomas. "
10/01/1999 - "Mice were treated with 131I-labeled di-DTPA-indium-tyrosyl-lysine bivalent hapten (75-112 MBq) administered 15-48 h after anti-CEA x anti-DTPA-indium BsF(ab')2. Immunohistological studies were performed on tumors at their minimal relative volume (TT), on stabilized tumor nodules (LS174T), and on regrowing tumors (TT and LS174T). "
10/01/2013 - "Gallium-68-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-cyclic Arg-Gly-Asp-D-Tyr-Lys (c(RGDyK)) was developed for αvβ3 targeting, and is a promising agent for imaging of cancer and disorders related to angiogenesis. "
2. Inflammation
08/15/2013 - "These results provide evidence that the Tyr-Lys-Asp region in both ET-3 and BPET3 is essential for marked inhibition of the peptide on PAF-induced inflammation, and strongly suggest that BPET3 may be useful as a novel anti-inflammatory drug targeting PAF."
10/15/2013 - "Accumulating evidence strongly suggests that ET-3, but not ET-1 and ET-2, can attenuate PAF-induced inflammation through direct binding of the Tyr-Lys-Asp (YKD) region in the peptide to PAF and its metabolite/precursor lyso-PAF, followed by inhibition of binding between PAF and its receptor. "
08/15/2013 - "We recently reported that synthetic biotinylated peptides having a Tyr-Lys-Asp-Gly sequence inhibit PAF-induced inflammation by directly binding to PAF. "
10/05/2015 - "In this study, synthetic heptapeptides (Lys-Trp-Tyr-Lys-Asp-Gly-Asp) coupled to a biotin molecule through the N-terminal amino group and ε-amino group of N-terminus Lys, (Btn)KP6 and K(Btn)P6, respectively, and their biotinylated peptides substituted with d-Lys at the N-terminus, (Btn)dKP6 and dK(Btn)P6, respectively, were investigated for their effects on PAF-induced inflammation. "
08/15/2013 - "In this study, we investigated the effect of two synthetic biotinylated peptides, both of which have a sequence similar to Tyr-Lys-Asp-Gly-an endothelin-3 (ET-3)-related biotinylated pentapeptide (Tyr-Lys-Asp-Lys-Glu, BPET3) and a scavenger receptor CD36-related biotinylated tetrapeptide (Tyr-Lys-Gly-Lys, BPCD36)-on PAF-induced inflammation by using a rat model of hind paw oedema. "
3. Tics (Tic)
4. Tyrosinemias (Tyrosinemia)
5. Sudden Infant Death (SID)

Related Drugs and Biologics

1. Peptides
2. aspartylglycine
3. Pentetic Acid (DTPA)
4. cyclo(arginylglycyl)
5. Scavenger Receptors (Scavenger Receptor)
6. Ethylene Glycol (Monoethylene Glycol)
7. Endothelin-3 (Endothelin 3)
8. Polyethyleneimine
9. Indium
10. Biotin (Vitamin H)